Product Description
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Ireland
Approved Indications: None
Known Adverse Events: None
Company: National Heart, Lung, and Blood Institute (NHLBI)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Death, Sudden, Cardiac|Coronary Artery Disease|Myocardial Infarction|Myocardial Ischemia|Cardiac Arrest
Phase 2: Death, Sudden, Cardiac|Myocardial Infarction|Cardiac Arrhythmias|Ventricular Fibrillation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CAST | P3 |
Completed |
Coronary Artery Disease|Myocardial Infarction|Death, Sudden, Cardiac|Cardiac Arrest|Myocardial Ischemia |
None |
|
| NCT00000504 | P2 |
Completed |
Cardiac Arrhythmias|Death, Sudden, Cardiac|Myocardial Infarction|Ventricular Fibrillation |
None |